Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda

被引:114
作者
Gray, RH
Li, XB
Wawer, MJ
Gange, SJ
Serwadda, D
Sewankambo, NK
Moore, R
Wabwire-Mangen, F
Lutalo, T
Quinn, TC
机构
[1] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Populat & Family Hlth Sci, Baltimore, MD USA
[2] Columbia Univ, Joseph L Mailman Sch Publ Hlth, Heilbrun Ctr Populat & Family Hlth, New York, NY USA
[3] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[4] Makerere Univ, Fac Med, Dept Med, Kampala, Uganda
[5] Makerere Univ, Fac Med, Sch Publ Hlth, Kampala, Uganda
[6] Uganda Virus Res Inst, Rakai Project, Entebbe, Uganda
[7] Johns Hopkins Univ Hosp, Dept Med, Baltimore, MD 21287 USA
[8] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[9] NIAID, NIH, Bethesda, MD 20892 USA
关键词
HIV; antiretroviral therapy; vaccines; stochastic simulation; Rakai;
D O I
10.1097/00002030-200309050-00013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To model the effects of antiretroviral therapy (ART) and HIV vaccines on HIV transmission using empirical data from studies in Rakai, Uganda. Design: A stochastic simulation model estimated HIV incidence, probabilities of transmission per coital act and the reproductive number (R-0) with ART and HIV vaccines. Model inputs included Rakai data on HIV transmission probabilities per coital act by HIV viral load, age and gender, and sexual behaviors. The impacts of therapy were derived from US programs, and vaccine assumptions included preventive efficacies ranging from 25 to 75%. Component projection models estimated the numbers of HIV-infected persons over 20 years. Results: The model incidence [1.57/100 person years (PY)] closely fitted empirical data (1.5/100 PY). Simulations of ART using DHHS treatment guidelines, predicted declines in HIV incidence, but R-0 remained > 1.0, and the numbers of HIV-positive persons did not change substantially over 20 years. Preventive vaccines with > 50% efficacy and > 50% population coverage could reduce R-0 to < 1.0, and substantially reduce the number of HIV-infected persons over 20 years. Concurrent ART and a preventive vaccine can have substantial impact at lower levels of population coverage and would markedly reduce the HIV infected population over 20 years. However, behavioral disinhibition with increased numbers of sexual partners in either ART or vaccine recipients, increased HIV incidence and diminished intervention impact. Conclusion: ART alone cannot control the HIV epidemic in mature epidemics such as Rakai, and persons in need of therapy will increase over time. ART in combination with a low efficacy vaccine could control the epidemic, if behavioral disinhibition is prevented. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:1941 / 1951
页数:11
相关论文
共 30 条
  • [1] Low-efficacy HIV vaccines: Potential for community-based intervention programmes
    Anderson, RM
    Garnett, GP
    [J]. LANCET, 1996, 348 (9033) : 1010 - 1013
  • [2] Arriaga E, 1994, POPULATION ANAL MICR
  • [3] The Women's Interagency HIV Study
    Barkan, SE
    Melnick, SL
    Preston-Martin, S
    Weber, K
    Kalish, LA
    Miotti, P
    Young, M
    Greenblatt, R
    Sacks, H
    Feldman, J
    [J]. EPIDEMIOLOGY, 1998, 9 (02) : 117 - 125
  • [4] Public health - HIV/AIDS treatment for millions
    Binswanger, HP
    [J]. SCIENCE, 2001, 292 (5515) : 221 - +
  • [5] A tale of two futures: HIV and antiretroviral therapy in San Francisco
    Blower, SM
    Gershengorn, HB
    Grant, RM
    [J]. SCIENCE, 2000, 287 (5453) : 650 - 654
  • [6] Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy.
    Bozzette, SA
    Joyce, G
    McCaffrey, DF
    Leibowitz, AA
    Morton, SC
    Berry, SH
    Rastegar, A
    Timberlake, D
    Shapiro, MF
    Goldman, DP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) : 817 - 823
  • [7] Adverse effects of antiretroviral therapy
    Carr, A
    Cooper, DA
    [J]. LANCET, 2000, 356 (9239) : 1423 - 1430
  • [8] Curtis H, 1998, LANCET, V352, P1379
  • [9] Davidson AC, 1997, BOOTSTRAP METHODS TH
  • [10] Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?
    Esparza, J
    Bhamarapravati, N
    [J]. LANCET, 2000, 355 (9220) : 2061 - 2066